ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout

Treatment Options for Severe Refractory Gout When Pegloticase Fails

Diana M. Girnita, MD, PhD, Cody Lee, MD, & Christine Chhakchhuak, MD  |  August 12, 2016

Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric acid (PUA) to less than 6…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:ClinicalGoutoutcomepegloticaseResearchrheumatologistrheumatologyTreatment

Patients with Gout May Not Understand Serum Urate Goals & Treatments

Richard Quinn  |  July 1, 2016

New research has found that a minority of gout patients understands the importance of their serum urate goals. Ted Mikuls, MD, MSPH, says the study shines a light on a gap in patient education providers can address…

Filed under:ConditionsGout and Crystalline ArthritisPractice Support Tagged with:AllopurinolGoutpatient educationtipstreatment goals

Rheumatology Coding Corner Answer: Coding for Acute Flare of Idiopathic Gout

From the College  |  December 17, 2015

Take the challenge. M10.072—Acute gout has an Excludes 1 note of chronic gout (M1A.-). This means that acute gout and chronic gout cannot be coded for the same encounter, as the codes are mutually exclusive. M45.6—The patient is diagnosed with ankylosing spondylitis of the lumbar region. M81.8—Other osteoporosis without current pathological fracture. M79.622—The patient has…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisPractice Support Tagged with:CodingCoding CornerDiagnosisGoutpatient carePractice ManagementrheumatologistTreatment

Rheumatology Coding Corner Question: Coding for Acute Flare of Idiopathic Gout

From the College  |  December 16, 2015

It has been two months since the implementation of ICD-10, so everyone has gotten a feel for the new code set. Let’s see how well you are doing in your diagnosis coding for rheumatology-specific conditions. A 55-year-old female patient presents for a follow-up visit of idiopathic chronic gout of multiple joints without tophi. She complains…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisPractice Support Tagged with:CodingCoding CornerDiagnosisGoutpatient carePractice ManagementrheumatologistTreatment

FDA Approves 2 Pain Drugs & New Gout Treatment on Road to Approval

Michele B. Kaufman, PharmD, BCGP  |  November 18, 2015

The FDA has approved two drugs designed to manage pain: buprenorphine for chronic pain and meloxicam capsules for OA pain. Lesurinad is also closer to FDA approval for treating gout…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates

New Gout Criteria from the ACR/EULAR Focus on Clinical Trials, Global Standards

Susan Bernstein  |  November 17, 2015

Gout affects nearly 4% of American adults, causing joint inflammation, pain and crystal deposits that may lead to bone erosion over time. At least five different classification criteria for gout are used worldwide, creating potential discrepancies in clinical trial enrollment and eventual results. An international panel of investigators collaborated to create new, standardized gout classification…

Filed under:Clinical Criteria/GuidelinesConditionsEULAR/OtherGout and Crystalline ArthritisMeeting ReportsPractice Support Tagged with:AC&RAmerican College of Rheumatology (ACR)Clinical GuidelinescriteriaDiagnosisEULARGoutManagementpatient careTreatment

Sleep Apnea Tied to Gout Flares

Kathryn Doyle  |  October 30, 2015

NEW YORK (Reuters Health)—Sleep apnea may increase the risk of developing gout and experiencing flare-ups, according to a new study. Until now, little was known about the relationship between the two conditions, the study team writes in an article online Oct. 19 in Arthritis & Rheumatology. Obesity plays an important role in both sleep apnea…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutsleep apneasleep disorderUric acid

Genetic Screening May Prevent Adverse Gout Treatment Reaction

Lara C. Pullen, PhD  |  October 26, 2015

Screening gout patients for the HLA-B*58:01 allele may help rheumatologists determine more effective treatments and a patient’s risk of allopurinol-induced severe cutaneous adverse reactions…

Filed under:ConditionsGout and Crystalline Arthritis

FDA Reviewers Question Safety of AstraZeneca’s Gout Drug

Amrutha Penumudi  |  October 23, 2015

(Reuters)—The U.S. Food and Drug Administration staff reviewers have raised concerns about kidney- and heart-related side effects noted in trials on AstraZeneca Plc’s gout treatment, especially at higher doses. FDA reviewers, in a preliminary review published on Wednesday, expressed concerns over higher death rates related to the side effects in patients who took the drug,…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:AstraZenecaFDAFood and Drug AdministrationGoutside effect

Patients May Be Right: Tomatoes May Trigger Gout Flares

Lara C. Pullen, PhD  |  October 5, 2015

Dietary triggers of gout flares are associated with high levels of serum urate. A study recently uncovered an association between high serum urate and tomatoes, the first such link established beyond patient anecdotes…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:DietflareGout

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 60
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences